| Similar Articles |
|---|
 |
The Motley Fool
April 20, 2011
Sean Williams |
KV Pharmaceuticals: From Sell to Belle in a Month Don't write off this company just yet.   |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
The Motley Fool
September 25, 2008
Brian Lawler |
Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors. |
Pharmaceutical Executive
May 1, 2011
Jill Wechsler |
Outrage Over Drug Prices Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies |
The Motley Fool
July 30, 2009
Brian Orelli |
A Little Help From the Enemy Unfortunately, it won't last. AstraZeneca went over a small patent cliff, but its competitors were nice enough to throw it some climbing gear. |
The Motley Fool
October 14, 2009 |
Today's 5-Star Movers Today's top-moving stocks from the Motley Fool five-star stock list: Lufkin Industries... KV Pharmaceutical... TETRA Technologies... |
Chemistry World
September 30, 2014
Phillip Broadwith |
Lumara splits and sells to AMAG and Perrigo Women's health specialist Lumara is to be split in two and sold to AMAG and consumer healthcare firm Perrigo. |
